Odensomab 60mg

Odensomab 60mg Injection contains the active ingredient Denosumab. This medication is utilized for the treatment of osteoporosis, a condition marked by weakened bones. Additionally, it is prescribed to avert bone complications in patients suffering from specific types of cancer, including multiple myeloma and bone metastases. Odensomab 60mg Injection functions by inhibiting a protein known as RANK ligand, which is involved in the degradation of bone tissue. Research has demonstrated that it can significantly enhance bone density, thereby lowering the risk of fractures in postmenopausal women with osteoporosis and in patients experiencing cancer-related bone loss. It may be necessary to closely monitor renal function in patients with moderate renal impairment.

Odensomab 60mg Injection is contraindicated for individuals with known hypersensitivity or allergic reactions to any of its components. Sufficient calcium and vitamin D supplementation is essential during the course of treatment. This medication is not authorized for use in children and adolescents, as its safety and efficacy in pediatric populations have not been established, making it contraindicated for individuals under 18 years of age. Caution is advised when administering this medication to individuals with pre-existing hypoparathyroidism, which is characterized by low levels of parathyroid hormone.